ArticleBlood advances2023
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 4 citations in OpenAlex.
- A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment.Cancer medicine · 2026Article
- Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance.Science China. Life sciences · 2026Review
- Appraisal of CRISPR Technology as an Innovative Screening to Therapeutic Toolkit for Genetic Disorders.Molecular biotechnology · 2026Review
- [Renal response and prognosis of newly diagnosed patients with multiple myeloma with renal impairment applying VRD and autologous hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.OncoTargets and therapy · 2025Article
- Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.International journal of hematology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
33 authors at 20 institutions in 1 country.
Yuan JianDepartment of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-4833-415X
Long ChangDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ming-Xia ShiDepartment of Hematology, The First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming, China.
Ying SunDepartment of Hematology, Chifeng Municipal Hospital, Chifeng, China.
Xiao-Xia ChuDepartment of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao, China.
Hua XueDepartment of Hematology, Affiliated Hospital of Hebei University, Baoding, China.
Wen-Rong HuangDepartment of Hematology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing, China.
Xu-Liang ShenDepartment of Hematology, Heping Hospital Affiliated To Changzhi Medical College, Changzhi, China.
Jie MaDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guo-Rong JiaDepartment of Hematology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China.
Ya-Qing FengDepartment of Hematology, The Third People's Hospital Of Datong, Datong, China.
Zhen-Fang XiDepartment of Hematology, Linfen People's Hospital, Linfen, China.
Yan-Hong ZhaoDepartment of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Yan-Ping MaDepartment of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China.
Jing XiaoDepartment of Hematology, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, China.
Guang-Yu MaDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Qing-Ming WangDepartment of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Li BaoDepartment of Hematology, Beijing Jishuitan Hospital, Beijing, China.ORCID 0000-0002-3975-9853
Yu-Jun DongDepartment of Hematology, Peking University First Hospital, Beijing, China.ORCID 0000-0002-7935-6194
He-Bing ZhouDepartment of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Chun-Yan SunInstitution of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guo-Hong SuThe Second Department of Hematology, Cangzhou Central Hospital, Cangzhou, China.
Yan YanDepartment of Hematology, Bayannur Hospital, Bayannur, China.
Sai-Yin QimugeDepartment of Hematology, Ordos Central Hospital, Ordos, China.
Li-Ping SuDepartment of Hematology, Shanxi Cancer Hospital, Taiyuan, China.
Jing-Nan SunDepartment of Oncology, The First Hospital of Jilin University, Changchun, China.
Wei-Wei TianDepartment of Hematology, Shanxi Bethune Hospital, Taiyuan, China.
Xiu-Li SunDepartment of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Hong-Mei JingDepartment of Hematology, Peking University Third Hospital, Beijing, China.
Da GaoDepartment of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Wen-Ming ChenDepartment of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Jian LiDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0002-4549-0694
Wen GaoDepartment of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNPeking University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNJilin University · CNAffiliated Hospital of Hebei University · CNBeijing Luhe Hospital Affiliated to Capital Medical University · CNBinzhou Medical University · CNCangzhou Central Hospital · CNChangzhi Medical College · CNChifeng Municipal Hospital · CNDalian Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CNHarbin Medical University · CNHebei Medical University · CNInner Mongolia Medical University · CNInner Mongolia University of Science and Technology · CNKunming Medical University · CNNanchang University · CNPeople's Liberation Army No. 150 Hospital · CNQingdao University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaRenal InsufficiencyBortezomibDexamethasoneHumansThalidomideBortezomibDexamethasonepomalidomideThalidomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.